MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

PTC Therapeutics Inc

Abierto

SectorSanidad

49.88 2.26

Resumen

Variación precio

24h

Actual

Mínimo

47.77

Máximo

49.97

Métricas clave

By Trading Economics

Ingresos

41M

-66M

Ventas

16M

213M

BPA

-0.342

Margen de beneficios

-30.907

Empleados

939

EBITDA

3M

-47M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+34.61% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

286M

3.8B

Apertura anterior

47.62

Cierre anterior

49.88

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

PTC Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2024, 12:47 UTC

Principales Movimientos del Mercado

PTC Therapeutics Shares Jump on Pact With Novartis

Comparación entre iguales

Cambio de precio

PTC Therapeutics Inc previsión

Precio Objetivo

By TipRanks

34.61% repunte

Estimación a 12 Meses

Media 66.7 USD  34.61%

Máximo 113 USD

Mínimo 50 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para PTC Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

6

Comprar

5

Mantener

1

Vender

Puntuación técnica

By Trading Central

48.255 / 49.95Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.